Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.
Ryotaro NakamuraWael SaberMichael J MartensAlyssa RamirezBart L ScottBetül OranEric LeiferRoni TamariAsmita MishraRichard T MaziarzJoseph P McGuirkPeter WesterveltSumithira VasuMirinal S PatnaikRammurti KambleStephen J FormanMikkael A SekeresFrederick AppelbaumAdam MendizabalBrent R LoganMary M HorowitzCorey S CutlerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
We observed a significant survival advantage in older subjects with higher-risk MDS who have a matched donor identified and underwent reduced-intensity HCT, when compared with those without a donor. HCT should be included as an integral part of MDS management plans in fit older adults with higher-risk MDS.